logo
  

Former CEO Of Exelon, Chris Crane, Passes Away At 65

Former chief executive officer of Exelon, Chris Crane, passed away at the age of 65. He died on April 13 in Chicago. He served as the company's president and chief executive officer from 2012 until his retirement in December 2022, the company said in a statement on Sunday.

Exelon noted that Crane steered the company through several transformational milestones including the successful mergers with Constellation Energy in 2012 and Pepco Holdings in 2016, creating the largest utility business by customer count, and the later creation of a standalone transmission and delivery company with the spinoff of the generation and retail energy business as Constellation Energy in 2022.

Chris Crane joined Exelon (then Unicom Corporation) in 1998 and was named chief nuclear officer in 2004. He was named president of Exelon Generation in 2007.

Chris Crane held several key industry roles throughout his career, including chair of the Edison Electric Institute, the Institute of Nuclear Power Operations, and the Nuclear Energy Institute. He also served as chair of the board of Chicago's Museum of Science and Industry and was a member of the board of the Economic Club of Washington, DC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Specialty medical devices provider Teleflex Inc. (TFX) reported Thursday that net income for the first quarter plunged to $15.29 million or $0.32 per share from $76.75 million or $1.62 per share in the prior-year quarter. Income from continuing operations was $0.33 percent, sharply lower than $1.63... Shares of Standard Chartered Plc were gaining more than 5 percent on the London Stock Exchange after the lending major reported Thursday higher profit in its first quarter, despite weak net interest income. The company further maintained its fiscal 2024 guidance. While reporting financial results for the first quarter on Wednesday, Kraft Heinz Co. (KHC) reaffirmed its adjusted earnings and organic net sales growth guidance for the full-year 2024. For fiscal 2024, the company still projects adjusted earnings in a range of $3.01 to $3.07 per share on organic...

This week, we feature OJEMDA’s FDA approval, Bristol Myer’s Job cuts, Novo Nordisk’s increased pricing of drugs in US, Incyte’s strategic acquisition, and Ireland’s Alcohol labels.

View More Videos
Follow RTT